For research and educational purposes only. Not medical advice.
MK-2866 Reference
Educational, not medical advice reference for MK-2866: SARM, Recovery; regulatory status, evidence posture, source review, and schedule notes. Also known as…
Reference summary
Most-studied SARM with completed Phase 3 cancer-cachexia trials. Despite trial-level lean-mass improvements, the program did not yield FDA approval. No body-composition trials in healthy adults exist.
- Categories
- SARM, Recovery
- Aliases
- Ostarine, Enobosarm, GTx-024, S-22, Non-steroidal SARM
- Evidence posture
- human — FDA enforcement attention. Sold only as a research chemical, not for human consumption per legal seller terms. WADA-prohibited under category S1.2 at all times. Failed Phase 3 in cancer cachexia (POWER trials) — no FDA approval followed. No human clinical efficacy program for body-composition use.
- Regulatory status
- No FDA-approved MK-2866 drug label. GTx ran Phase 3 trials (POWER 1 and POWER 2) in non-small-cell lung cancer cachexia; the program failed to meet co-primary endpoints, and FDA approval did not follow. WADA prohibits MK-2866 under category S1.2 anabolic agents at all times. FDA has issued explicit consumer warnings against SARMs in bodybuilding products.
- Content review status
- research reference